Maravai Lifesciences Holdings(MRVI)
$7.38+0.10 (+1.37%)
MRVI
Maravai Lifesciences Holdings financials statements
$7.38
At close:+0.10 (+1.37%)
Want to see MRVI full AI Analyst Report?
Maravai Lifesciences Holdings (MRVI) Ratios
426 Followers
Maravai Lifesciences Holdings Ratios
MRVI's free cash flow for Q3 2026 was $4.49M. For the 2026 fiscal year, MRVI's free cash flow was decreased by $-523.00K and operating cash flow was $5.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.60 | 7.53 | 8.00 | 7.70 | 7.89 |
| Quick Ratio | 5.69 | 6.65 | 7.41 | 7.31 | 7.34 |
| Cash Ratio | 4.83 | 5.66 | 6.57 | 5.74 | 5.88 |
| Solvency Ratio | -0.18 | -0.20 | -0.10 | 0.19 | 0.15 |
| Operating Cash Flow Ratio | -1.28 | 0.13 | 1.44 | 4.87 | 3.93 |
| Short-Term Operating Cash Flow Coverage | -10.58 | 1.37 | 23.20 | 98.53 | 61.43 |
| Net Current Asset Value | $ -101.61M | $ -1.89M | $ 2.35M | $ -529.17M | $ -632.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.37 | 0.41 | 0.26 | 0.30 |
| Debt-to-Equity Ratio | 0.17 | 1.16 | 1.47 | 1.07 | 1.82 |
| Debt-to-Capital Ratio | 0.14 | 0.54 | 0.59 | 0.52 | 0.65 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.47 | 0.55 | 0.49 | 0.62 |
| Financial Leverage Ratio | 3.63 | 3.10 | 3.57 | 4.19 | 6.08 |
| Debt Service Coverage Ratio | -4.42 | -2.92 | -0.85 | 21.24 | 14.46 |
| Interest Coverage Ratio | -0.25 | -4.94 | -0.69 | 28.13 | 18.33 |
| Debt to Market Cap | 0.04 | 0.21 | 0.32 | 0.15 | 0.06 |
| Interest Debt Per Share | 0.43 | 3.08 | 4.98 | 4.60 | 5.27 |
| Net Debt to EBITDA | 1.23 | -0.35 | 0.05 | -0.08 | 0.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 17.98% | 41.79% | 48.52% | 80.87% | 82.41% |
| EBIT Margin | -111.97% | -82.48% | 229.67% | 64.77% | 70.19% |
| EBITDA Margin | -79.42% | -60.54% | 246.56% | 69.08% | 73.29% |
| Operating Profit Margin | -3.63% | -90.91% | -10.95% | 65.03% | 69.40% |
| Pretax Profit Margin | -126.50% | -100.89% | 213.79% | 62.45% | 66.41% |
| Net Profit Margin | -70.41% | -55.89% | -41.19% | 24.94% | 22.78% |
| Continuous Operations Profit Margin | -124.24% | -100.17% | -47.89% | 55.57% | 58.71% |
| Net Income Per EBT | 55.65% | 55.39% | -19.27% | 39.93% | 34.30% |
| EBT Per EBIT | 3487.30% | 110.98% | -1951.90% | 96.04% | 95.69% |
| Return on Assets (ROA) | -16.97% | -14.37% | -8.00% | 9.65% | 9.49% |
| Return on Equity (ROE) | -61.58% | -44.53% | -28.56% | 40.39% | 57.70% |
| Return on Capital Employed (ROCE) | -0.93% | -24.77% | -2.26% | 26.44% | 30.40% |
| Return on Invested Capital (ROIC) | -0.91% | -24.24% | 0.50% | 23.39% | 26.73% |
| Return on Tangible Assets | -26.71% | -22.17% | -12.66% | 12.36% | 11.05% |
| Earnings Yield | -27.74% | -19.27% | -13.78% | 11.70% | 3.78% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.28 | 6.73 | 5.19 | 6.01 | 6.80 |
| Payables Turnover | 0.00 | 12.62 | 13.86 | 28.20 | 17.24 |
| Inventory Turnover | 3.76 | 3.01 | 2.89 | 3.92 | 2.73 |
| Fixed Asset Turnover | 152.75 | 1.19 | 1.30 | 7.57 | 8.38 |
| Asset Turnover | 0.24 | 0.26 | 0.19 | 0.39 | 0.42 |
| Working Capital Turnover Ratio | 0.60 | 0.53 | 0.43 | 1.28 | 1.89 |
| Cash Conversion Cycle | 147.12 | 146.48 | 170.19 | 140.97 | 166.37 |
| Days of Sales Outstanding | 50.11 | 54.25 | 70.39 | 60.69 | 53.67 |
| Days of Inventory Outstanding | 97.02 | 121.16 | 126.12 | 93.22 | 133.88 |
| Days of Payables Outstanding | 0.00 | 28.93 | 26.33 | 12.94 | 21.17 |
| Operating Cycle | 147.12 | 175.40 | 196.51 | 153.91 | 187.55 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.40 | 0.05 | 0.96 | 4.07 | 3.21 |
| Free Cash Flow Per Share | -0.49 | -0.16 | 0.46 | 3.94 | 3.08 |
| Dividend Paid and CapEx Coverage Ratio | -4.38 | 0.25 | 1.93 | 31.36 | 24.82 |
| Capital Expenditure Coverage Ratio | -4.38 | 0.25 | 1.93 | 31.36 | 24.82 |
| Operating Cash Flow Coverage Ratio | -1.62 | 0.02 | 0.21 | 0.92 | 0.64 |
| Operating Cash Flow to Sales Ratio | -0.31 | 0.03 | 0.44 | 0.61 | 0.46 |
| Free Cash Flow Yield | -15.00% | -2.95% | 7.02% | 27.57% | 7.35% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.57 | -5.19 | -7.26 | 8.55 | 26.42 |
| Price-to-Sales (P/S) Ratio | 2.54 | 2.90 | 2.99 | 2.13 | 6.02 |
| Price-to-Book (P/B) Ratio | 2.22 | 2.31 | 2.07 | 3.45 | 15.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.67 | -33.87 | 14.24 | 3.63 | 13.60 |
| Price-to-Operating Cash Flow Ratio | -8.19 | 100.68 | 6.85 | 3.51 | 13.05 |
| Price-to-Earnings Growth (PEG) Ratio | 0.27 | -0.31 | 0.05 | 1.70 | -0.34 |
| Enterprise Value Multiple | -4.86 | -9.46 | 2.36 | 5.80 | 15.67 |
| Enterprise Value | 716.28M | 1.49B | 1.68B | 3.54B | 9.18B |
| EV to EBITDA | -4.86 | -9.46 | 2.36 | 5.80 | 15.67 |
| EV to Sales | 3.86 | 5.73 | 5.82 | 4.01 | 11.49 |
| EV to Free Cash Flow | -10.13 | -66.92 | 27.71 | 6.82 | 25.95 |
| EV to Operating Cash Flow | -12.44 | 198.94 | 13.32 | 6.60 | 24.91 |
| Tangible Book Value Per Share | 0.63 | 1.61 | 1.84 | 3.08 | 2.40 |
| Shareholders’ Equity Per Share | 1.46 | 2.36 | 3.16 | 4.14 | 2.75 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | 0.01 | 1.22 | 0.11 | 0.12 |
| Revenue Per Share | 1.28 | 1.88 | 2.19 | 6.71 | 6.96 |
| Net Income Per Share | -0.90 | -1.05 | -0.90 | 1.67 | 1.59 |
| Tax Burden | 0.56 | 0.55 | -0.19 | 0.40 | 0.34 |
| Interest Burden | 1.13 | 1.22 | 0.93 | 0.96 | 0.95 |
| Research & Development to Revenue | 0.13 | 0.07 | 0.06 | 0.02 | 0.02 |
| SG&A to Revenue | 0.92 | 0.62 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.19 | 0.12 | 0.02 | 0.01 |
| Income Quality | 0.44 | -0.03 | -1.06 | 1.09 | 0.79 |
Currency in USD

